(Q30000824)

English

Placebo cohorts in phase-3 MS treatment trials - predictors for on-trial disease activity 1990-2010 based on a meta-analysis and individual case data

scientific article (publication date: 2012)

In more languages

Statements

scholarly article

0 references

1 reference

based on heuristic

inferred from title

Placebo cohorts in phase-3 MS treatment trials - predictors for on-trial disease activity 1990-2010 based on a meta-analysis and individual case data (English)

0 references

phase III clinical trial

0 references

0 references

1

object named as

Jan-Patrick Stellmann

0 references

Christoph Heesen

8

object named as

Christoph Heesen

0 references

author name string

Anneke Neuhaus

2

0 references

Lena Herich

3

0 references

Sven Schippling

4

0 references

Matthias Roeckel

5

0 references

Martin Daumer

6

0 references

Roland Martin

7

0 references

language of work or name

0 references

publication date

2012

0 references

0 references

7

0 references

11

0 references

e50347

0 references

copyright license

Creative Commons Attribution 4.0 International

29 November 2012

1 reference

April 2022 Public Data File from Crossref

copyright status

0 references

Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3510222

21 May 2017

A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3510222

21 May 2017

Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3510222

21 May 2017

A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3510222

21 May 2017

Diagnostic criteria for multiple sclerosis: 2005 revisions to the “McDonald Criteria”

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3510222

21 May 2017

Recommended diagnostic criteria for multiple sclerosis: Guidelines from the international panel on the diagnosis of multiple sclerosis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3510222

21 May 2017

Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3510222

21 May 2017

Placebo-controlled trial of oral laquinimod for multiple sclerosis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3510222

3 June 2018

Trends in annualized relapse rates in relapsing-remitting multiple sclerosis and consequences for clinical trial design.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3510222

3 June 2018

Assessing changes in relapse rates in multiple sclerosis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3510222

3 June 2018

A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3510222

3 June 2018

Will Rogers phenomenon in multiple sclerosis.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3510222

3 June 2018

Predicting gadolinium enhancement status in MS patients eligible for randomized clinical trials

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3510222

3 June 2018

Advanced methods in meta-analysis: multivariate approach and meta-regression.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3510222

3 June 2018

A comparison of summary patient-level covariates in meta-regression with individual patient data meta-analysis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3510222

3 June 2018

Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG)

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3510222

3 June 2018

Predictors of relapse rate in MS clinical trials.

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0050347

21 January 2018

Explaining heterogeneity in meta-analysis: a comparison of methods.

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0050347

21 January 2018

Intravenous immunoglobulin treatment in multiple sclerosis. Effect on relapses.

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0050347

21 January 2018

Randomized trial of oral teriflunomide for relapsing multiple sclerosis.

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0050347

21 January 2018

Incidental MRI anomalies suggestive of multiple sclerosis: the radiologically isolated syndrome

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0050347

21 January 2018

Randomised double-blind placebo-controlled study of interferon β-1a in relapsing/remitting multiple sclerosis

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0050347

21 January 2018

MRI as an outcome in multiple sclerosis clinical trials

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0050347

21 January 2018

Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. The IFNB Multiple Sclerosis Study Group

1 reference

https://pubmed.ncbi.nlm.nih.gov/23209717

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Randomised placebo-controlled trial of monthly intravenous immunoglobulin therapy in relapsing-remitting multiple sclerosis. Austrian Immunoglobulin in Multiple Sclerosis Study Group

1 reference

https://pubmed.ncbi.nlm.nih.gov/23209717

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group

1 reference

https://pubmed.ncbi.nlm.nih.gov/23209717

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1371/JOURNAL.PONE.0050347

0 references

2012PLoSO...750347S

0 references

PMC publication ID

0 references

PubMed publication ID

0 references

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q30000824&oldid=2001509267"